← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
  1. Home
  2. XOMA
  3. P/E History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

XOMA logoXOMA Royalty Corp. (XOMA) P/E Ratio History

Historical price-to-earnings valuation from 2009 to 2025

Current P/E
28.3
Undervalued
5Y Avg P/E
70.7
-60% vs avg
PE Percentile
33%
Below Avg
PEG Ratio
2.12
Expensive
TTM EPS$1.63
Price$41.29
5Y PE Range7.8 - 353.6
Earnings Yield3.54%

Loading P/E history...

XOMA Valuation Context

How does the current P/E compare to historical and market benchmarks?

vs. 5Y Average
28.3vs70.7
-60%
Cheap vs History
vs. Healthcare
28.3vs22.3
+27%
Above Sector
vs. S&P 500
28.3vs25.1
+13%
Above Market
PEG Analysis
2.12
P/E ÷ EPS Growth
PEG > 2 = Expensive
Based on 188% EPS growth (1Y)
Export Data

P/E Ratio Analysis

As of May 8, 2026, XOMA Royalty Corp. (XOMA) trades at a price-to-earnings ratio of 28.3x, with a stock price of $41.29 and trailing twelve-month earnings per share of $1.63.

The current P/E is 60% below its 5-year average of 70.7x. Over the past five years, XOMA's P/E has ranged from a low of 7.8x to a high of 353.6x, placing the current valuation at the 33th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.3x, XOMA trades at a 27% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.

The PEG ratio of 2.12 (P/E divided by 188% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, XOMA trades roughly in line with the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our XOMA DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

XOMA P/E vs Peers

P/E ratio compared to closely matched public peers

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
RPRX logoRPRXRoyalty Pharma plc
$22B27.93.95-6%
OMAB logoOMABGrupo Aeroportuario del Centro Norte, S.A.B. de C.V.
$5B16.70.44Best+8%
PFE logoPFEPfizer Inc.
$151B19.5--4%
MRK logoMRKMerck & Co., Inc.
$277B15.4Lowest0.73+8%
ABBV logoABBVAbbVie Inc.
$358B85.5--1%
BMY logoBMYBristol-Myers Squibb Company
$115B16.3-+178%Best

Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.

XOMA Historical P/E Data (2009–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterDatePriceTTM EPSP/E Ratiovs Avg
FY2025 Q4Wed Dec 31 2025 00:00:00 GM$26.59$1.4718.1x-74%
FY2025 Q3$38.54$0.7650.9x-28%
FY2022 Q3Fri Sep 30 2022 00:00:00 GM$17.91$0.5731.4x-56%
FY2022 Q2$22.28$0.5342.0x-41%
FY2022 Q1$27.98$0.8632.5x-54%
FY2021 Q4Fri Dec 31 2021 00:00:00 GM$20.85$0.4249.6x-30%
FY2021 Q3$24.75$0.07353.6x+400%
FY2021 Q2Wed Jun 30 2021 00:00:00 GM$34.00$0.3693.8x+33%
FY2021 Q1Wed Mar 31 2021 00:00:00 GM$40.81$0.23175.7x+149%
FY2020 Q4$44.13$0.40109.7x+55%
FY2018 Q2Sat Jun 30 2018 00:00:00 GM$20.88$2.339.0x-87%
FY2018 Q1Sat Mar 31 2018 00:00:00 GM$20.23$2.607.8x-89%

Average P/E for displayed period: 70.7x

See XOMA's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is XOMA Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare XOMA vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

XOMA — Frequently Asked Questions

Quick answers to the most common questions about buying XOMA stock.

Is XOMA stock overvalued or undervalued?

XOMA trades at 28.3x P/E, below its 5-year average of 70.7x. At the 33th percentile of historical range, the stock is priced at a discount to its own history.

How does XOMA's valuation compare to peers?

XOMA Royalty Corp. P/E of 28.3x compares to sector median of 22.3x. The premium reflects expected growth above peers.

What is XOMA's PEG ratio?

XOMA PEG ratio is 2.12. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2009-2025.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

XOMA P/E Ratio History (2009–2025)

P/E ratio calculated as closing price divided by trailing 12-month diluted EPS at each quarter end.